Literature DB >> 31698935

Insight Into the Mechanism of Macroreentrant Atrial Tachycardia With Cycle Length Alternans Using Ultrahigh Density Mapping System.

Jinlin Zhang1, Liangrong Zheng2, Dongchen Zhou2, Anquan Zhao3, Cheng Tang1, Yonghua Zhang1, Xi Su1.   

Abstract

BACKGROUND: Atrial tachycardia (AT) with cycle length (CL) alternans is a rare phenomenon. We aimed to identify the characteristics and precise mechanism of this special category of ATs by using an ultrahigh density mapping system.
METHODS: We identified 7 ATs with alternating CL in a total of 478 ATs from 2 institutions mapped with an ultrahigh density mapping system. Activation maps were performed for long CL (289±35 ms; mapping points, 21 520±11 103) and short CL (251±18 ms; mapping points,17 594±8059) separately.
RESULTS: We classified ATs with CL alternans into 2 types. Type 1: There existed 2 potential loops with different routes. CL alternans resulted from an intermittently 2:1 conducting block within the channel of the smaller loop. Type 2: CL alternans resulted from different conduction velocity through 2 closely spaced gaps within preexisting linear lesions. Catheter ablation successfully terminated all the 7 ATs.
CONCLUSIONS: Ultrahigh density mapping provides an opportunity to delineate the precise mechanism of AT with CL alternans. Intermittent conduction block or slowing of a channel was essential for the maintenance of AT.

Entities:  

Keywords:  catheter ablation; electrodes; patient selection; subclavian vein; tachycardia

Mesh:

Year:  2019        PMID: 31698935     DOI: 10.1161/CIRCEP.119.007634

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  1 in total

1.  Microvolt QRS Alternans Without Microvolt T-Wave Alternans in Human Cardiomyopathy: A Novel Risk Marker of Late Ventricular Arrhythmias.

Authors:  Adrian Suszko; Sachin Nayyar; Christopher Labos; Kumaraswamy Nanthakumar; Arnold Pinter; Eugene Crystal; Vijay S Chauhan
Journal:  J Am Heart Assoc       Date:  2020-08-18       Impact factor: 5.501

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.